Lupin rose 2.24% to Rs 880.20 at 13:21 IST on BSE, with the stock extending Thursday's 1.03% gains triggered by the company's US subsidiary announcing the launch of its generic Gatifloxacin Ophthalmic Solution 0.5% in the United States.
Meanwhile, the S&P BSE Sensex was up 90.96 points or 0.46% at 19,993.03.
On BSE, 1.12 lakh shares were traded in the counter as against average daily volume of 1.19 lakh shares in the past one quarter.
The stock hit a high of Rs 886.80 and a low of Rs 857 so far during the day. The stock had hit a record high of Rs 908 on 19 July 2013. The stock had hit a 52-week low of Rs 540.15 on 11 October 2012.
The stock had underperformed the market over the past one month till 3 October 2013, advancing 2.45% compared with the Sensex's 9.14% rise. The scrip had also underperformed the market in past one quarter, gaining 3.61% as against Sensex's 3.78% rise.
The large-cap company has equity capital of Rs 89.60 crore. Face value per share is Rs 2.
More From This Section
Shares of Lupin have risen 3.29% in two trading sessions from a recent low of Rs 852.10 on 1 October 2013 after the company during trading hours on Thursday, 3 October 2013 said its US subsidiary Lupin Pharmaceuticals Inc. (LPI) has launched its generic Gatifloxacin Ophthalmic Solution, 0.5% in the United States. The stock had risen 1.03% to settle at Rs 860.95 on Thursday, 3 October 2013.
Lupin had earlier received final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of Allergan Inc.'s Zymaxid Ophthalmic Solution, 0.5%.
Lupin's Gatifloxacin Ophthalmic solution 0.5% is the generic equivalent of Zymaxid Ophthalmic Solution of Allergan and is indicated for the treatment of bacterial conjunctivitis. Zymaxid Ophthalmic Solution, 0.5%, had annual sales of approximately $62.3 million in the US according to IMS MAT Jun 2013 data. Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Zymaxid Ophthalmic Solution and as such will be entitled to 180 days of marketing exclusivity.
Lupin's consolidated net profit surged 43% to Rs 401.06 crore on 9.1% growth in net sales to Rs 2420.66 crore in Q1 June 2013 over Q1 June 2012.
Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients.
Powered by Capital Market - Live News